Regeneron Pharmaceuticals says it will acquire 23andMe's assets, including its Personal Genome Service, for $256M, set to close in Q3, in the bankruptcy auction
But What Happens to Your Data? David Braue / Information Age : Biotech buys bankrupt DNA data firm 23andMe for $400m Naomi Li Gan / Tech in Asia : Pharma giant Regeneron to buy genetics firm 23andMe for $256m Fred Pennic / HIT Consultant : Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services Fernanda Tronco / TheStreet : Major biotech company acquired after Chapter 11 bankruptcy Rocket Drew / The Information : Regeneron to Buy 23andMe for $256 Million MarketWatch : Dow Jones Top Company Headlines at 7 PM ET: Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million | Jamie ... Frank Vinluan / MedCity News : 23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron's Gene-Based Drug R&D Efforts Matt Binder / Mashable : Now we know who's getting 23andMe's DNA data. Meet Regeneron Pharmaceuticals. Maggie Harrison Dupré / Futurism : Bankrupt 23andMe Just Sold Off All Your DNA Data Ian Bradley / KTVU-TV : 23andMe to be acquired by NY-based Regeneron in $256 million deal Michael Kan / PCMag : 23andMe Finally Has a Buyer: How Will Regeneron Handle Your DNA Data? Financial Times : 23andMe sold out of bankruptcy to Regeneron Dan Primack / Axios : 23andMe assets being sold to Regeneron Pharma for $256M Bluesky: Jason Koebler / @jasonkoebler : FYI: under capitalism your DNA is worth $17 — www.404media.co/23andme-sale... Michel Nivard / @michelnivard : This is VERY big genetics & health news, Regeneron (Pharmaceutical company with v strong genetics in medicine arm) is going to buy 23andme. investor.regeneron.com/news- release... Mary Branscombe / @marypcbuk : Without knowing the company, at least it seems like big pharma can do something with your genetic data that's hopefully not sell it to insurance companies [embedded post] Mastodon: Joseph Cox / @josephcox@infosec.exchange : So judging by the $256 million dollar sale of 23andMe, your genetic data is worth like $17 — https://www.404media.co/... X: @23andme : We have reached a sale agreement with @Regeneron, a leading US-based biotechnology company, to carry forward 23andMe's mission and maintain customer privacy protections. Read more about today's announcement here: https://www.globenewswire.com/ ... Linea / @lindaavey : Regeneron acquires @23andMe. So all the data end up in the hands of one pharma company. Not the outcome we envisioned but could have been worse (eg PE). https://www.globenewswire.com/ ... Pearl Freier / @pearlf : Amgen bought deCODE genetics for $415M in cash in 2012 & it's still an Amgen subsidiary 13 yrs later. Today, Regeneron is announced as 23andMe's buyer for $256M in a court- supervised sale. 23andMe will continue as a subsidiary of Regeneron w/ commitment to safeguard data: 1/n [image] @regeneron : 📣Today we announced that we intend to acquire @23andMe with plans to maintain their consumer genetics business and advance our shared goal of improving human health and wellness. https://investor.regeneron.com/ ... LinkedIn: Marc Sluijs : Interesting development as Regeneron buys 23andMe ... (Lemonaid Health (part of 23andMe) may still be up for sale?). … Forums: r/genetics : Regeneron buys 23andMe r/23andme : Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million r/MEstock : Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale | 23andMe, Inc. r/biotech : Regeneron to acquire 23andMe for $256 million
Context & Ripple Effects
23andMe’s Chapter 11 filing put its business and data-linked assets into a value-maximizing process after a sharp reversal from its earlier multibillion-dollar valuation. The proposed buyer arrives after the bankruptcy filing that opened the company to a sale.
The company had already established that its consumer genetics operation could support drug research, including an earlier Genentech data partnership for Parkinson’s research. The sale therefore shifts stewardship of a consumer-facing genomics platform into a biotech owner while data protection remains central to the transaction.
First-order effects
- Regeneron becomes the proposed owner of 23andMe’s key assets, including its consumer genome service, pending the court-supervised sale and expected closing.
- 23andMe customers would move to a new prospective data steward; Regeneron’s pledge to continue the service and safeguard genetic information becomes an immediate trust and execution test.
Second-order effects
- The bankruptcy auction turns the platform’s consumer and research assets into an explicit acquisition target, giving other potential bidders a benchmark for valuing a genetics business under distress.
- Privacy safeguards will receive heightened scrutiny in any transfer, particularly against allegations that 23andMe inadequately protected sensitive information in its 2023 breach.
Third-order effects
- If biotech companies increasingly acquire consumer-genomics platforms, consumer genetic datasets may become more tightly integrated with drug-discovery operations rather than remaining stand-alone testing businesses.
- The pattern would make governance of consent, security, and ownership-transfer terms a core constraint on the market for health-data assets, not merely a customer-service issue.
The trend: Consumer genomics is moving from a stand-alone testing proposition toward a strategic data and research asset for established biotech buyers, with privacy governance determining how transferable that value is.